Celgene Corp. (CELG)

95.24
NASDAQ : Health Technology
Prev Close 95.63
Day Low/High 95.19 / 96.02
52 Wk Low/High 58.59 / 97.07
Avg Volume 8.63M
Exchange NASDAQ
Shares Outstanding 705.26M
Market Cap 67.44B
EPS 5.70
P/E Ratio 14.60
Div & Yield N.A. (N.A)
Biotechs and Builders Will Rock 2Q Earnings

Biotechs and Builders Will Rock 2Q Earnings

A look at who will be up and who will down this earnings season.

Cramer: 10 Stocks That Need to Start Doing Better

Cramer: 10 Stocks That Need to Start Doing Better

They need to do something that makes them stand out as stocks you want to own, not avoid.

Celgene Shares Likely to Jump on Potential $2B 'Orphan' Drug: RBC

Celgene Shares Likely to Jump on Potential $2B 'Orphan' Drug: RBC

Shareholders could be in for a surprise if an upcoming drug for pediatric Crohn's gains FDA approval.

5 Stocks I Like for 2016's Second Half

5 Stocks I Like for 2016's Second Half

From Celgene to Ford, these names look promising.

Cramer: Might Something Be Brewing in 3 Downtrodden Sectors?

Biotech, restaurants and retail have been left for dead but are showing signs of life today.

Stocks Feeling the Pressure of 'Brexit', Italian Banks Weakness

Stocks Feeling the Pressure of 'Brexit', Italian Banks Weakness

There are renewed worries about Brexit as the British pound has fallen to a new 30 year low.

My Takeaways and Observations

My month was made by Double D's comments, and I mean it.  At my core I am a softie, and D's sweet words tugged at my heart. I shared them with my family. Bottom line to me on the markets: This week's events reset global economic and profits growth l...

Worst Is Yet to Come for Celgene?

The stock could be bottoming ... or headed lower.

3 Finds in Biotech's 'Pocket of Value'

3 Finds in Biotech's 'Pocket of Value'

Large biotech stocks are still at their cheapest valuations since 2011.

One Direction, Separate Leadership Positions Prove Vital to Celgene’s Success

One Direction, Separate Leadership Positions Prove Vital to Celgene’s Success

While many companies combine the roles of the CEO and Chairman of the Board, Celgene has found success in keeping those duties separate.

Looking for Relief From Biotech Pain

A lost leader in Celgene and a Perrigo rumor have put a scare in the charts.

Cramer: Here's What's Really Behind This Hatred for Biotechs

This is the group that is the most dangerous politically.

Takeaways and Observations

My thanks to James Gentile for substituting for me yesterday. Here are my takeaways and observations from yesterday's session: It was Groundhog Day on Wall Street again. We finished down, but well off of the session lows. I did no trading. The U.S. ...

My Takeaways and Observations

Buyers live higher, sellers live lower. Markets are still Fed-centric and governed by the last lean by Yellen. Ali Ali Ali!  Here's a very good column from El Capitan.   Apple (AAPL) is Crapple (Part Deux)  Fastenal (FAST) is always a good proxy for...

My Latest Trades

Here's a rundown of the trades that I've made so far this morning: I sold my SPY June $208 puts at breakeven a few minutes ago. There are only two weeks left until this put expires, so I'm moving on. I've liquidated the balance of my four-stock biot...

My Morning Musings

Phil (played by Bill Murray): What would you do if you were stuck in one place and every day was exactly the same, and nothing that you did mattered? Ralph: That about sums it up for me. -- Groundhog Day Wednesday was a relatively uneventful trading...

My Takeaways and Observations

Venezuela is the new Greece.  Icahn goes for some Allergan (AGN) -- a name of mine -- but his impact is muted after missteps in the energy space and elsewhere.   Nobody likes short people,  but I grow shorter daily. (Note: We got little hands and li...

Celgene May Be Ready to Stage a Recovery

CELG needs to close above its April highs to kickstart a rally to around the $120 area.

If You Like Watching Paint Dry, Today's Your Day!

Here are random observation on a day that was like watching paint dry! Bonds are near the day's high, with iShares 20+ Year Treasury Bond ETF (TLT) up 75 cents, and bank stocks are near the day's lows. Limited volatility along most industry sectors ...

Adding to a Quintet of Longs

I am back buying Hartford Financial Services Group (HIG) and the four members of my Biotech Basket -- Allergan (AGN), Intrexon (XON), Gilead Sciences (GILD) and Celgene (CELG).

My Takeaways and Observations

The day started with the challenges in the sneaker field.  Bloomberg on Goldman Sachs and Morgan Stanley analysts' Tesla (TSLA) price target hikes -- I believe (and am quoted) that these moves go against the spirit of the law.    I remember CNBC's M...

Today's Trades

Here's a recap what I've done so far today: I added to my longs of Hartford Financial (HIG) and Oaktree Capital (OAK). I substantially increased my short of the Consumer Staples Select Sector SPDR ETF (XLP), which is our Short Trade of the Week. I i...

Is Biotech About to Go from Goat to Hero?

I've previously written that I've been poised to buy biotechs again, but that I wanted to see some more evidence of price confirmation. After all, this volatile space has punished anticipatory traders so far this year. (Sometimes I agree with my Rea...

My Takeaways and Observations

Did I mention that the market has no memory from day to day? It was a busy short-side day for me today. Disney (DIS) -- why the mouse is no longing roaring.   On management B.S.  Macy's (M).   Sears (SHLD) is the elephant in the room and a possible ...

Why Celgene, Fiserv & Travelers Should Be Bought

Why Celgene, Fiserv & Travelers Should Be Bought

Celgene shares are off 16 percent year-to-date and last week's weak guidance did not enthuse the biotech giant's backers.

Cramer: Get Ready for More Downgrades for Tech and Biotech

It's mighty tough to put a multiple on a declining business.

Celgene's Charts Are Healthy, This Stock Is Ready to Recover

Improving momentum suggests we could have an intermediate-term rally, possibly taking CELG above $120.

Some Stocks Are Really Cheap

Some Stocks Are Really Cheap

There are lots of winners in the first quarter.

My Takeaways and Observations

I started the day and ended the day at my highest net short exposure in over one-and-a-half years. I had my head in two research projects today rather than in the markets. It's just as well, given the action. Remember bulls/buyers live higher and be...

What Earnings Season Shows So Far

What Earnings Season Shows So Far

This will still be fourth quarter in a row that profits have declined year over year.